Recent data clearly show that we are extremely ineffective in the use of lipid-lowering therapy (LLT). Furthermore, the problem seems to be the most serious in the group of patients at very high and extremely high-risk – the patients who stand to benefit most from effective therapy.
2022: the year in cardiovascular disease - the year of upfront lipid lowering combination therapy
Cicero AFGWriting – Original Draft Preparation
;
2022
Abstract
Recent data clearly show that we are extremely ineffective in the use of lipid-lowering therapy (LLT). Furthermore, the problem seems to be the most serious in the group of patients at very high and extremely high-risk – the patients who stand to benefit most from effective therapy.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Banach M_2022 the year in cardiovascular disease_ Arch Med Sci.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Condividi allo stesso modo (CCBYNCSA)
Dimensione
70.05 kB
Formato
Adobe PDF
|
70.05 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
